about
Management of hepatitis delta: Need for novel therapeutic optionsHepatitis viruses (other than hepatitis B and C viruses) as causes of hepatocellular carcinoma: an updatePrevalence and genotype distribution of hepatitis delta virus among chronic hepatitis B carriers in Central Vietnam.Epidemiology of acute and chronic hepatitis B and delta over the last 5 decades in ItalyProteoglycans act as cellular hepatitis delta virus attachment receptors.High prevalence and significance of hepatitis D virus infection among treatment-naïve HBsAg-positive patients in Northern Vietnam.Co-treatment with pegylated interferon alfa-2a and entecavir for hepatitis D: A randomized trial.Delineating HIV-associated neurocognitive disorders using transgenic models: the neuropathogenic actions of Vpr.The management of chronic hepatitis B in Asian Americans.Experimental models and therapeutic approaches for HBV.Animal models of chronic hepatitis delta virus infection host-virus immunologic interactions.Epidemiology of hepatitis D virus (HDV) infection in an urban area of northern Italy.Viral hepatitis and liver cancer.Epidemiology of hepatitis D in patients infected with hepatitis B virus in bucharest: a cross-sectional study.Molecular and clinical aspects of hepatitis D virus infections.Implication of reported viral hepatitis incidence rate change in Hubei Province, China, between 2004-2010.Immunoglobulin M anti-hepatitis D virus in monitoring chronic hepatitis delta.An expert consensus for the management of chronic hepatitis B in Asian Americans.Hepatitis D, B and C virus (HDV/HBV/HCV) coinfection as a diagnostic problem and therapeutic challenge
P2860
Q28082312-BE017E49-BE00-49AA-A88F-E359BE931722Q28284989-0E767CA3-7267-49AB-A871-6C1D896A802DQ33558023-DBBB97B6-8486-4D72-BFB0-F6DDDB2DDA80Q33801300-5F46DE92-34AE-4B42-94B4-1E97EE832250Q34625734-2433B565-BAC2-4285-83BF-9038F4593A8FQ35036020-488C9AF4-4D86-4EA8-8DCC-1BEDB7B99782Q36902633-1980DF22-25E7-4853-A8B0-5D7622F2C91AQ37932423-33EB6ADD-ADB5-4DD9-886D-EF327C1B71A8Q37936321-351194E3-8A95-4820-8CE5-0D4087DDDAF3Q38035173-615110BA-4A60-4F66-8C9D-822CFB0CAD80Q38357110-ABC93BE0-73A9-4508-B6A9-8520179029FEQ40023495-C828E429-7243-4BC0-9ACF-4590E1677B78Q40046596-7E7DD9DA-0929-41EC-99EB-484B1744100DQ42275105-C22C1769-8AC8-4576-919E-ADCCBB2A1F6EQ42969554-F07E80A4-D0BE-429C-B146-DE3775B958CEQ43536340-53A0CDAC-1B4C-42DD-BE76-A2A12B3C6A71Q45365066-5522BC3E-1B2C-49BE-A5E7-6B1AC1F618E8Q52685884-FF7A9243-5D7B-431F-98CA-7A27F46B902CQ56947386-78D14875-BBA3-4C82-96CF-26ED10F7CEBF
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Hepatitis D revival.
@en
Hepatitis D revival.
@nl
type
label
Hepatitis D revival.
@en
Hepatitis D revival.
@nl
prefLabel
Hepatitis D revival.
@en
Hepatitis D revival.
@nl
P1433
P1476
Hepatitis D revival.
@en
P2093
Heiner Wedemeyer
P2860
P304
P356
10.1111/J.1478-3231.2010.02408.X
P478
31 Suppl 1
P577
2011-01-01T00:00:00Z